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ABSTRACT
The Putative Cannabinoid Receptor GPR55 Modulates
Synaptic Plasticity in the Hippocampus
Corinne Marie Badgley
Department of Physiology and Developmental Biology, BYU
Master of Science in Neuroscience
Endocannabinoids (eCBs) are small molecules that are capable of modulating synaptic plasticity
of both excitatory and inhibitory synapses in the brain. While eCBs bind to transient receptor
potential vanilloid 1 (TRPV1) and cannabinoid receptor 1 (CB1) in the central nervous system,
we recently identified a form of non-CB1, non-TRPV1 mediated long term depression activated
by the eCB anandamide at CA1 hippocampal stratum radiatum interneurons. GPR55, an orphan
G-protein receptor, has been identified in the hippocampus and is capable of activation by eCBs,
making it a good candidate for mediating this non-CB1, non-TRPV1 form of synaptic plasticity.
Here we performed whole-cell patch clamp recordings from CA1 stratum radiatum interneurons
in rat brain slices to investigate the effect of GPR55 agonist O-1602 on excitatory synapses. We
also performed field recordings from CA1 pyramidal cells in rats and GPR55 knockout mice and
littermate controls to investigate the effect of GPR55 agonists O-1602 and
lysophosphatidylinositol (LPI) on both basal output and electrically induced long-term
depression and long-term potentiation in the hippocampus. Application of O-1602 in rats
depressed long-term potentiation in CA1 pyramidal cells, and depressed excitatory glutamatergic
transmission onto some interneurons. O-1602 had no effect on long-term depression of CA1
pyramidal cells. GPR55 +/+ mice showed an increase in long-term potentiation in the presence of
LPI compared to GPR55-/- littermates. GPR55-/- mice had no change in long-term potentiation
when exposed to O-1602, though there was an increase in post-tetanic potentiation with O-1602.
In order to examine whether GPR55 has a role in formation of spatial memory, GPR55 -/- mice
were compared to littermate controls during a Morris water maze behavioral task, with a reversal
task after 7 days of training. GPR55-/- mice did not perform in a different manner on either the
training task or the reversal, though there may be a trend of difference in training worth
investigating further. This study illustrates a novel pathway for synaptic plasticity modulation
through GPR55 in the hippocampus, and may therefore provide valuable insight into both the
effects of synthetic and endogenous cannabinoids on the brain and the processes underlying
learning and memory.
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INTRODUCTION
The hippocampus is required for learning and memory in humans and other mammals
and has vast interconnections with the limbic system, cortical association areas and the prefrontal
cortex. It has been implicated in many processes, including consolidation of memory of recent
events (Scoville and Milner, 2000), declarative memory (Squire, 1992), and encoding spatial and
contextual information (Burgess et al., 2002). All of these events are thought to occur by the
inherent synaptic plasticity observed between hippocampal neurons. The mechanisms behind
these short-term changes in synaptic plasticity are thought to be related to long-term potentiation
(LTP) (Bliss and Collingridge, 1993), and long-term depression (LTD) (Dudek and Bear, 1992),
which increase and decrease synaptic strength respectively.

LTP and LTD in the Hippocampus:
LTP depends on strengthening synapses and may be involved in encoding memories
through increasing the number of active 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic
acid receptors (AMPAR) postsynaptically, increasing the size of the synapse, or increasing the
amount of presynaptic neurotransmitter release (Malenka and Bear, 2004). LTD in the
hippocampus occurs by decreasing postsynaptic receptor density or decreased presynaptic
release of neurotransmitter, and may be responsible for clearing old memory traces (Nicholls et
al., 2008, Malleret et al., 2010). LTD is of key importance in synaptic plasticity because it allows
the continuous alteration of synapses, allowing animals to alter behavior as new information is
presented (Nicholls et al., 2008). The processes underlying synaptic plasticity in the
hippocampus occur by activation of different presynaptic and postsynaptic receptor types.
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Initial research on synaptic plasticity focused on N-methyl-D-aspartate receptor
(NMDAR) mediated synaptic plasticity, but recently increased attention has been given to LTP
and LTD gated or altered by endocannabinoid (eCB) receptors, as it became apparent that
processes other than NMDAR-initiated mechanisms are capable of modulating synaptic
plasticity.

Cannabinoids and Plasticity:
Cannabinoid receptors are sensitive to the exogenous psychoactive component of the
marijuana plant Cannabis sativa, '9-tetrahydrocannabionol (THC). Recently, eCBs or
endogenous cannabinoids have been implicated as the natural activators of these receptors. eCBs
have been found to work as retrograde messengers within the hippocampus. This form of eCBmediated synaptic plasticity has been observed in the hippocampus at both excitatory (Gerdeman
and Lovinger, 2003) and inhibitory synapses. For example, eCBs have been found to depress
inhibitory GABAergic cells presynaptically via cannabinoid receptor 1 (CB1) in a process
termed “depolarization-induced suppression of inhibition” (DSI) (Kreitzer and Regehr, 2002).
DSI can occur in response to activation from Schaffer collaterals of group I metabotropic
glutamate receptor 5 (mGluR5) on CA1 pyramidal cells, which initiate production of eCBs that
activate CB1 receptors of nearby cholecystokinin (CCK)-containing interneurons thereby
inhibiting the release of GABA (Katona et al., 1999, Hoffman and Lupica, 2000). Another form
of postsynaptic mGluR/eCB-dependent LTD was demonstrated to link excitatory
neurotransmission and postsynaptic mGluRs with eCB mediated heterosynaptic depression of
GABA release from cannabinoid-sensitive interneurons in the stratum radiatum of the
hippocampus (Chevaleyre and Castillo, 2003), which results in enhanced CA1 pyramidal cell

2

LTP (Chevaleyre and Castillo, 2004). This research indicates that eCBs are involved in
modulating synaptic plasticity in the hippocampus by DSI, and suggest their potential
contribution to the processes of learning and memory.
In addition, other somewhat contrasting research has indicated that eCB activation of
CB1 can also initiate depression of CA1 LTP directly. Recently it has been demonstrated that
both cannabinoid agonists and antagonists can depress LTP in acute slices, as well as impair
spatial learning in in vivo rat experiments (Abush and Akirav, 2010). While these experiments
show that eCBs have an effect on behavior, and especially for hippocampal spatial learning and
memory, it has been difficult to draw direct relationships between specific ligand-binding and
expected effects. This may be because the eCB system has diverse targets, with different eCB
receptors initiating separate signal cascades within the hippocampus. Prior evidence shows that
CBs can inhibit CA1 LTP, an effect that can be blocked by CB1 antagonist, however varying
results have been gained with different agonist concentrations and stimulation methods (Davies
et al., 2002), which also may imply that eCBs are effective to different targets at different
concentrations. Thus far it can be concluded that eCBs modulate synaptic plasticity, but their
mechanisms of actions and their downstream effects are less clear.
It has also been proposed that eCBs may activate a non-CB1 receptor to mediate acute
depression at the CA3-CA1 excitatory synapse (Hajos and Freund, 2002, Rouach and Nicoll,
2003, Nemeth et al., 2008) and recently eCBs have been shown to induce LTD at interneurons in
the stratum radiatum by an unknown non-CB1, non-transient receptor potential vanilloid 1
(TPRV1) receptor (Edwards et al., 2010). These findings indicate that eCB signaling is capable
of affecting hippocampal output by unknown pathways or receptors. A candidate receptor
initiating the eCB-mediated depression of CA1 interneurons has yet to be proposed.
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G Protein-Coupled Receptor 55:
A possible non-CB1 cannabinoid receptor candidate involved in hippocampal plasticity is
G-protein receptor 55 (GPR55), an orphan G-protein coupled receptor with wide distribution
throughout the brain that can be activated by THC, lysophosphatidylinositol (LPI), and most
eCBs including anandamide, 2-arachidonylglycerol (2-AG), as well as CB1 antagonists AM251
and SR141716A (Sharir and Abood, 2010). It has been proposed as a novel cannabinoid receptor
capable of functioning in the peripheral nervous system separate from CB1, and has been found
to initiate a cascade that increases intracellular calcium in neurons of the dorsal root ganglion
(Ryberg et al., 2007, Lauckner et al., 2008). GPR55 has been found in the rat hippocampus by in
situ hybridization (Sawzdargo et al., 1999), and GPR55 mRNA has been reported in the mouse
hippocampus (Ryberg et al., 2007) as well as in tissues outside the central nervous system. Its
function in the hippocampus however, has not been examined. Its potential as an
endocannabinoid target, as well as an initiator of internal calcium release makes GPR55 an
intriguing contender as a non-CB1/non-TRPV1 modulator of synaptic plasticity. GPR55 has also
been found in several other tissues, and has been proposed as a promoter of cancer cell
proliferation (Andradas et al., 2011), a regulator of osteoclast number and function (Whyte et al.,
2009), and as a regulator of inflammatory and neuropathic pain (Staton et al., 2008). The
downstream effects and signaling mechanisms have been reported to vary with both ligand
binding and tissue specificity, which may allow this receptor to mediate various processes within
the body (Henstridge et al., 2010), including altering signaling in the hippocampus.
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Behavioral Effects of Cannabinoids:
The effects of cannabinoids such as THC on behavior are well documented, and include
alterations in memory and cognitive ability (Chaperon and Thiebot, 1999). Altered behaviors
induced by cannabinoids are manifestations of synaptic plasticity in the brain (Lupica et al.,
2004). eCBs anandamide and 2-AG are present in the hippocampus in high concentrations, and
their effects are not fully explained by activation of CB1 alone (Di Marzo et al., 2000). If
GPR55 is an eCB target capable of modulating synaptic plasticity shown though
electrophysiology, it may also play a role in altering behavior. In order to investigate the role of
GPR55 in hippocampal function through behavior, the Morris water maze (Brandeis et al., 1989)
has been employed. The goal of this behavioral component to our research is to examine whether
there is a link between alterations in electrically induced synaptic plasticity via GPR55 and
learning and memory in mice. The involvement of GPR55 was examined by comparing the
performance (quantified in latency times) on the maze of GPR55 -/- mice to GPR55 +/+ mice.
The widespread expression of GPR55 makes discovering its function and mechanism of
action within the hippocampus pressing research, as it may modulate learning and memory
systems in mammals in addition to having applications in other fields of research. Here, we find
evidence supporting GPR55 as a potential eCB target capable of modulating hippocampal
synaptic plasticity and neurotransmission. Our research indicates depression of transmission at
some, but not all CA3-CA1 interneurons. This study also indicates that GPR55 modulates
synaptic plasticity by depressing CA1 LTP, supporting prior research showing that eCBs may
initiate different effects on hippocampal function. Further investigation will need to be done in
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order to comment definitively on whether GPR55 -/- mice have different capabilities in spatial
memory compared to GPR55+/+ mice.
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MATERIALS AND METHODS
Preparation of Brain Slices:
Male Sprague-Dawley rats aged P15-27 (Charles River) and male GPR55 knockout and
wild type mice P16-32 (University of North Carolina via the Mutant Mouse Regional Resource
Center) were used in these studies. Animals were housed in approved conditions with a 12 h
light-dark cycle. The experiments were conducted in accordance with the Brigham Young
University Institutional Animal Care and Use Committee standards and National Institute of
Health guidelines to minimize pain and suffering of animals. All animals were deeply
anesthetized with isoflurane using a vapomatic chamber and decapitated, following which their
brains were removed rapidly and placed in ice-cold, oxygenated medium containing (in mM):
NaCl, 119; NaHCO 3 , 26; KCl, 2.5; NaH 2 PO 4 , 1.0; CaCl 2 , 2.5; MgSO 4 , 0.6; glucose, 11;
saturated with 95% O 2 , 5% CO 2 (pH 7.4). The posterior aspect of the brain was glued with
cyanoacrylate adhesive to the cutting stage of a vibratome DIWHUZKLFKȝPFRURQDOVOLFHV
were cut and then transferred to a holding chamber containing oxygenated artificial cerebrospinal
fluid (ACSF) at room temperature. This cutting technique maintains the integrity of the
hippocampal circuitry.

Slice Electrophysiology:
Following an interval of at least 1 h, slices were transferred to a submerged recording
chamber and perfused with oxygenated ACSF medium of the same composition as that in the
holding chamber at a temperature between 28-32oC. Slices were continuously perfused with
ACSF at a flow rate of 2-3 ml/min. A bipolar stainless steel stimulating electrode was placed in
the stratum radiatum, at least 400-ȝPIURPWKHUHFRUGLng electrode to stimulate CA3
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glutamatergic afferents of the Schaffer Collateral pathway at 10-ȝ$IRUȝVHFDW0.1Hz
sampling rate. Recordings were performed in current clamp mode to measure excitatory
postsynaptic potentials using an Axopatch 200B amplifier. Data was filtered at 4 kHz and
acquired with an axon 1440A digitizer (Molecular Devices) and inputted onto a Dell personal
computer (OptiPlex 745) with pClamp10.2 clampex software (Molecular Devices). Stimulation
intensity was adjusted to elicit an EPSP of 0.5 mV at the beginning of each experiment.
Borosilicate glass patch pipettes (2-0 ZHUHILOOHGZLWK01D&OIRUILHOGUHFRUGLQJ
electrodes. EPSPs were evoked and monitored for at least 60 minutes.
Whole-cell recordings were performed in voltage clamp at -65 mV using a multiclamp
700B amplifier (Molecular Devices) and EPSCs are evoked by two pulses separated by 50msec.
Borosilicate glass patch pipettes (2-4 0) were filled with Cs+-gluconate based internal
solutions containing (in mM): NaCl, 2; MgCl 2 , 5; HEPES, 20; ATP, 2; GTP, 0.3 and EGTA, 0.6.
AMPAR-mediated currents were measured while blocking GABA A receptors with bicuculline or
picrotoxin (10PM). Stable baseline recordings of AMPAR-mediated currents were obtained at
the frequency of 0.1 Hz.

Morris Water Maze:
The water maze consisted of a large, circular pool (1.67 m in diameter, .4 m in height). A
clear platform (7.6 cm in diameter) was placed inside, and the tank was filled with water (22°C)
until the top of the platform was submerged by 1 cm. A sufficient amount of powdered skim
milk (Augason Farms) was added to make the water opaque and conceal the platform. Four
sheets of paper with black and white geometric designs served as visual cues and were attached
to four areas of camera scaffolding around the pool. Swim paths were recorded by digital
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overhead camera (HeroHD) for each subject, and escape latencies (the time between being
placed in the water and finding the platform) were recorded using a stopwatch.
Pre-training acclimation sessions consisting of free swim in the pool for 5 min without
the platform were performed the day before acquisition trials began. Acquisition trials occurred
over seven consecutive days of four trials per day. The position of the platform remained fixed
for all trials for all mice. Four points along the periphery of the pool served as trial start points
designated North, South, East, and West, where the mice would be placed facing the wall of the
pool. Each starting point was used once per session, with order determined arbitrarily by the
tester. Once the platform had been located, the mouse was allowed to stay for 30 s before
removal. If a subject failed to locate the platform in less than 120 s, it was manually guided.
After the initial seven acquisition sessions, mice were subjected to a reversal test in which the
platform was moved to the opposite side of the pool. All other task parameters remained the
same.

Analysis:
For field recordings, the maximal initial value of EPSPs slopes was calculated using
pClamp10.2 clampfit software (Molecular Devices). EPSPs measured every 10 s were averaged
in 1 minute intervals. Values were normalized to control slope values 5 minutes immediately
prior to high frequency stimulus, and subjected to t-tests (paired, two-tailed, p < 0.05). An
increase in EPSP slope that persisted for longer than 60 min indicated that LTP had been
induced. EPSP normalized slope values were compared for significance (unpaired, two tailed ttest) 20-25 min post high frequency stimulus between rat or mouse brain slices treated or not
treated with O1602. Only one experiment was performed per slice and the reported n is the
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number of slices not the number of animals. Microsoft Excel and Origin (North Hampton, MA)
were used to organize, average, graph and to perform statistical analysis on the data.
For whole cell recordings, methods were similar to field recordings, but the EPSC
amplitude was determined by measuring against a 10 ms baseline prior to evoking EPSC. The
average pre-theta burst AMPAR current from a period of 5 minutes was then compared to a 5minute period 15-20 minutes post-theta burst to determine statistical significance, using a t test
(p < 0.05). Theta burst was used to mimic more natural hippocampal activation patterns. Two
bursts were given 20 seconds apart. The cell input resistance was monitored throughout the
experiment and if changed by more than 10%, the cell was discarded. Interneurons were
distinguished from pyramidal cells visually, electrophysiologically and by their higher input
resistance.
For statistics of the Morris water maze task, a life regression was conducted to assess the
effects of genotype and sessions/trials. Life regression analysis was used in order to account for
trials where mice did not find the platform in under 120 sec. These trials are counted as a time
above 120 sec, and confidence intervals are used to arrive at predicted median escape latency.
An interaction of gender was also tested since both male and female subjects were used.

Materials:
All salts were purchased from Sigma-Aldrich, Mallinkrodt-Baker or Fisher Scientific.
Bicuculline was purchased from Ascent Scientific. Picrotoxin and Lysophosphatidylinositol were
purchased from Sigma-Aldrich. O-1602 was purchased from Tocris, Abcam and Ascent
Scientific.
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RESULTS
GPR55 is a strong candidate for a novel form of synaptic plasticity that does not occur
through the expected CB1 mediated pathway because of its ability to bind eCBs and its potential
to activate different signal cascades (Sharir and Abood, 2010). In addition, a function for GPR55
in the hippocampus has not yet been postulated, though its binding has been linked to several
different signaling pathways in other regions indicating that it could play a role in modulating
synaptic plasticity by a novel mechanism. Therefore, we first wanted to confirm GPR55 receptor
expression in the hippocampus. Using quantitative real-time PCR (RT-PCR) we identified the
expression of GPR55 in rat hippocampal homogenate (Fig. 1). The GPR55 cDNA from
hippocampal homogenates was amplified in a dose dependent manner, demonstrating the
presence of GPR55 in increasing cycle number as expected. After amplification, GRP55 cDNA
was run out on a 4% agarose gel to indicate the appropriate amplicon size (Fig. 1 inset). From
these data we can corroborate that GPR55 is present in rat hippocampus.
We were specifically focused on the CA3-CA1 interneuron synapse as one location to
examine eCB modulation because we recently identified a non-CB1/TRPV1 receptor-mediated
depression at this synapse in response to anandamide, indicating that an additional eCB receptor
is present there (Edwards et al., 2010). In order to examine GPR55 expression at the CA3-CA1
interneuron synapse, whole cell patch clamp recordings were performed on CA1 interneurons
with GPR55 agonist O- ȝ0 2-1602 caused a slight non-significant (p>0.05) depression
DWȝ0 )LJ$ KRZHYHUVRPHLQGLYLGXDOFHOOVZHUHVLJQLILFDQWO\GHSUHVVHG )LJ% $VD
control we examined CA1 pyramidal cells by application of O- ȝ0 ZKLFKGLGQRW
depress fEPSPs in CA1 pyramidal cells in any experiments (Fig. 2C).
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Next, in the process of investigating the role of GPR55 in synaptic plasticity, we wanted
to investigate whether LTP was altered when induced using theta-burst protocol in the presence
of GPR55 agonist. This was done while recording field excitatory postsynaptic potentials
(fEPSPs) from rat hippocampal CA1 pyramidal cells in the stratum radiatum. We confirmed that
O-1602 (1 ȝ0 DSSOLFDWLRQUHVXOWHGLQVLJQLILFDQWO\ p < 0.05) reduced LTP when compared to
EtOH vehicle control (Fig. 3A). We next examined the effect of O-1602 on LTD, and whether
LTD was altered using 1 Hz stimulation in the presence and absence of O- ȝ0 :HGLG
not observe a significant (p>0.05) difference between trials run with O-1602 and those run with
EtOH vehicle control (Fig. 3B).
While the O-1602 data is suggestive that GPR55 is involved in modulating hippocampal
plasticity, a GPR55 antagonist is needed to confirm this finding. However, just as there are no
consistently reported agonists of GPR55, there are no uniformly accepted antagonists (Sharir and
Abood, 2010). Agents cannabidiol and O-1819 have both been show to inhibit GPR55 in some
but not all cases, and their effects on other receptors make them less than ideal negative controls.
Therefore, the most reliable negative control for GPR55 experiments is the use of the transgenic
GPR55-/- mouse.
While using GPR55 littermate and knock-out mice we also chose to broaden our use of
agonists to LPI in order to increase our certainty and specificity of activating GPR55, as LPI is
an endogenous ligand of GPR55 whereas O-1602 is a manufactured abnormal cannabinoid
agonist. It was important to examine the effects of both agonists on GPR55-/- mice and their
GPR55 +/+ littermates to isolate the effects of these drugs to GPR55 as opposed to other targets.
We repeated theta burst induction of CA1 LTP using LPI as a GPR55 agonist in GPR55-/- mice
and their GPR55 +/+ littermates. Interestingly and in contrast to O-1602 data, LPI caused a
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significantly (p <0.05) enhanced LTP in the GPR55 +/+ mice as compared to GPR55-/- mice (Fig.
$ /3, ȝ0 DOVRFDXVHGDQHQKDQFHPHQWRI/73LQ*35 +/+ mice compared to EtOH
controls. While this increase was not significant (p > 0.05) LPI caused a substantial 14 ± 3% in
LTP compared to EtOH controls (Fig. 4B). In contrast, LPI did not cause any enhancement of
LTP (.07 ± 3%) compared to EtOH controls (Fig. 4C) in GPR55-/- mice.
The contrasting results of our O-1602 data raised the question of whether O-1602 was
acting specifically on GPR55 to decrease LTP in the rat model. If a receptor other than GPR55
was mediating the observed reduction in LTP, we would continue to see a reduction of LTP in
GPR55-/- mice. In order to examine this possibility, we induced LTP with a theta burst protocol
in the presence of O-1602 (ȝ0 RU(W2+FRQWUROVXVLQg GPR55-/- mice (Fig. 5). There was not
a significant difference (p>0.05) in LTP induced with and without O-1602 in GPR55-/- mice,
though some difference was observed between the post-tetanic potentiation (PTP) with O-1602
treated slices, which have a greater PTP than EtOH controls (16 ±5%). Since O-1602 had no
other effect in GPR55-/- mice, it suggests that reduction of LTP in the rat is due to O-1602
activation of GRP55, a result that may be indicative of physiological or functional differences
between GPR55 in rat and mouse models.
There are no reports of behavioral testing for spatial memory of GPR55 -/- and GPR55+/+
mice, but no differences have been observed in their phenotype or motor skills. Before data
collection, mice were observed during the 5 min pretraining session to detect any phenotypic
differences in their initial reactions to being placed in water. At the beginning of each session
both genotypes were placed into the water facing the pool wall from one of four start points
designated North, South, East, and West, and immediately approached the sides of the pool.
Initially all mice swam around the perimeter of the pool and spent progressively less time there
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as the pretraining session continued. Two of the GPR55 -/-(29%) and two of the GPR55 +/+ (29%)
mice had more labored swimming, characterized by rapid, jerky movements. These mice
improved over subsequent training sessions, but were still less likely to stay on the platform and
have smooth movements compared to other mice. No other health or motor deficits were
observed. At the time of the 5-min pretraining session mice ranged in age from 1.5 to 2 months.
The training session consisted of 7 consecutive days where mice searched for the stationary
platform four times from four different start points, and two groups were compared to see if
GPR55 played a role in learning spatial navigation. Life regression revealed significant decreases
in escape latencies (p<0.05) across training sessions for both WT and KO mice (Fig. 6A, B),
indicating that both groups were learning the location of the platform over time. Although no
significant differences were detected between genotypes (p=0.13), there was a trend towards
GPR55-/-mice having increased escape latencies. This behavior indicates a possible impediment
in navigational learning for GPR55-/-mice, although more experiments will need to be done to
determine this. For the probe trial, the platform was moved to the opposite side of the pool, and
the two genotypes were compared by trial. Figure 6C depicts the results of the reversal test in
which the platform was placed on the opposite side of the pool. Escape latencies were not
significantly affected by genotype (p>0.05). This result indicates that there is no difference
between the GPR55 -/- and GPR55+/+ mice in ability to replace the previously learned platform
location.
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DISCUSSION
This study is the first to examine the function of GPR55 in the hippocampus as a
mediator of non-CB1/non-TRPV1 eCB-mediated synaptic plasticity. Specifically, our
observations confirm that GPR55 is present in the hippocampus, suggest that LPI enhances LTP
in mice via GPR55 and that O-1602 depresses LTP in rats through a mechanism that is likely
independent of GPR55. eCB mediated modulation of synaptic plasticity in the hippocampus is a
burgeoning area of research, and more data must be collected in order to create a clearer image
of the role of GPR55 in the hippocampus and standardize methods for investigating its effects in
the central nervous system.
In previous research, our lab had identified a form of eCB mediated, non-TRPV1/nonCB1 depression of CA1 interneurons. We chose to target GPR55 as a candidate for this effect
because of its ability to bind eCBs such as anandamide, its presence in the hippocampus
confirmed in our lab by RT-PCR (Fig. 1), and its downstream effectors that have the potential to
alter neuronal plasticity by release of intracellular calcium. While other GPCRs such as GPR119
are also good candidates for eCB mediated changes in neurons, GPR55 is comparatively wellcharacterized and had been reported active in the nervous system, making it a natural first target.
GPR119 has yet to be found active in the nervous system, and is predominately expressed in the
gastrointestinal system as a mediator of insulin secretion, though our lab has confirmed its
expression in rat hippocampal homogenate. GPR55 had been the target of research as a putative
third cannabinoid receptor, capable of mediating physiological changes in cells that cannot be
from CB1, CB2, or TRP receptors. No research has been published to date about the function of
hippocampal GPR55, and thus there is no precedent for our research.
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LPI increases LTP via GPR55 in the mouse model:
Agonists and antagonists of GPR55 are not well agreed upon, so to test whether GPR55
is capable of modulating synaptic plasticity, we needed a reliable negative control. We found that
the most reliable negative controls available are GPR55-/- mice. We decided to use
lysophosphatidylinositol (LPI) as an agonist, as it is arguably the most potent activator of GPR55
identified thus far for our transgenic mouse experiments. LPI is found in high concentrations in
the brain, and as a lipid breakdown product could be a downstream effecter of other agonists to
activate GPR55. It has also been shown to activate GPR119, so it is not a GPR55 specific
agonist, highlighting the importance of using GPR-/- mice as negative controls.
In GPR+/+ littermate controls we observed a significant increase in LTP in the presence of
LPI compared to LTP in GPR-/- mice (Fig. 4A). Increased LTP was not present in GPR-/- mice,
confirming that GPR55 modulates this increase in LTP, and that its activation is sufficient to
increase hippocampal LTP in transgenic mice (Fig. 4C). Since we had previously confirmed
GPR55 in rat hippocampus, and had observed a novel form of eCB-mediated depression in rat
CA1 interneurons, we wanted to examine whether GPR55 agonist would produce the same
GPR55 mediated increase in LTP observed in GPR55+/+ mice in a rat model.

O-1602 initiates synaptic plasticity of CA1 interneurons and CA1 pyramidal cells in rat:
As stated before, the agonists of GPR55 are hotly debated, and those that are generally
agreed upon are not exclusive for GPR55. We set out to see whether these agonists could
potentially mediate the depression at CA1 interneurons that we had originally observed in the
presence of R-methanandamide in rats, and potentially be the effecter of the increased CA1 LTP
we had observed in transgenic mice. We decided to use O-1602, an abnormal cannabinoid that
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has been reported as a potent agonist of GPR55 in some reports, though others have found it to
be inactive in different models.
We first wanted to see if O-1602 modulated CA1 pyramidal cell synaptic plasticity
induced by theta burst protocol to induce LTP as we had observed previously in GPR55+/+ mice.
We found that in the presence of O-1602, LTP in acute rat brain slices was reduced (Fig. 3A).
These results may corroborate with the fact that hippocampal eCB receptors can cause reduction
in CA1 LTP (Davies et al., 2002, Abush and Akirav, 2010). This decrease in LTP is opposite of
what we had observed in the transgenic mice, indicating that O-1602 could be acting through
other receptors to modulate synaptic plasticity. Although we observed a decrease in LTP induced
in the presence of this putative GPR55 agonist, no effect was observed when LTD was inducted
in the presence of O-1602 (Fig. 3B). This result indicates that the receptors binding O-1602 do
not modulate LTD induced by 1 Hz stimulation. This would suggest that the cascade initiated by
GPR55 activation, or at least receptors that bind O-1602 do not affect the processes underlying
LTD. It may be that CA1 LTP is necessary to observe a change mediated by targets of O-1602.
A decrease in LTP could be attributed to a direct effect on CA1 pyramidal cells possibly
modulating intracellular cascades, or an increase in GABA inhibition from interneurons,
therefore we examined whole cell recordings from CA1 interneurons to see if O-1602
application caused a change in current.
Whole-cell patch clamp recordings of rat CA1 interneurons showed depression in
response to O-1602 in some cases though not in others (Fig. 2A, B). This could be due to the
heterogeneity of CA1 interneurons. It would be beneficial to pull cells for quantitative RT-PCR
that have been recorded from in order to classify whether O-1602 causes depression in specific
interneuron subtypes. If GPR55 is in fact active at some CA1 interneuron subtypes it may reduce
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output by decreasing presynaptic CA3 glutamate release as suggested by our paired pulse ratio
data.
In order to test whether O-1602 is acting specifically through GPR55, we used GPR55-/mice as an indicator of GPR55 activity. There was no difference in LTP of GPR55-/- acute mouse
slices that were treated with O-1602 or EtOH control ACSF, however, there does appear to be a
difference in the post-tetanic potentiation (PTP), or the plasticity induced directly after the theta
burst protocol (Fig. 5). In the presence of O-1602, there is an increased PTP, which could be
interpreted to mean that O-1602 does activate a receptor other than GPR55 that is involved in
PTP, but not the long-term changes of LTP. It is possible that more than one receptor works in
concert in response to O-1602 to cause disinhibition. There is also the possibility that rats and
mice express these receptors in different levels with different effectors, and that their activation
initiates different outcomes. Past research has revealed significant differences in the behavioral,
pharmacological, and molecular structures of mice hippocampus compared to rat hippocampus
(McNamara et al., 1996). It is important to consider such differences when attempting to
replicate or build upon data across species.

Spatial memory in GPR55+/+ and GPR55-/- mice:
The hippocampus is known to function in the processes of learning and memory, and
more specifically area CA1 functions in storing spatial memory. GPR+/+ and GPR-/- mice have
not been found to differ in phenotype or in motor skills thus far, but this is the first study
investigating their potential differences in spatial memory. While both GPR+/+ and GPR-/- mice
had a significant improvement in escape latency over each session, there were no significant
differences between genotypes (Fig. 6A, B). However, it might be argued that there is a
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meaningful difference of increased latency times of GPR55 -/- mice that indicate an increase in
sample sizes for both groups may be worthwhile to confirm a significant difference between
performance of GPR+/+ and GPR-/- mice. An increased latency time in GPR55-/- mice would
corroborate our results that GPR55-/- mice had reduced LTP compared to their littermate controls,
and indicate that GPR55 is normally involved in spatial navigation tasks. An issue with this data
set is the large number of trials per session in which mice failed to reach the platform under the
120 sec time limit. This further reduces the amount of data we have reflecting the time it takes
each genotype to find the platform, and could potentially be solved by using a smaller pool or
larger platform. We controlled for this effect by using a life regression to analyze this data, in
order to take into account the trials that can only be accurately described as over 120 sec.

Is GPR55 a cannabinoid receptor?
As research into GPR55 is relatively new, a complicating issue in observing its effects is
the disagreement that exists over what its agonists and antagonists are, and whether they are the
same in all cell types, as few results have been replicated. Our results show that GPR55 is
capable of modulating synaptic plasticity as shown by our use of transgenic knockout mice.
These mice are extremely important to specific research into GPR55 until more specific agonists
and antagonists can be developed. O-1602 is also a modulator of synaptic plasticity in the
hippocampus, but its specific targets are not well defined (Schicho et al., 2011). O-1602 is an
abnormal cannabinoid that binds GPR55 (Johns et al., 2007) and the abnormal cannabidiol (abnCBD) receptor (McHugh et al., 2010). O-1602 is also a CB1 agonist, and CB1downstream
effects could cause depression, an effect that could be tested by the use of GPR55-/-. However,
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for this investigation we attempted to control for activation of CB1 by using concentrations of O1602 well below the 30PM concentration at which CB1 is activated.
We also used LPI as an agonist to assist in clarifying the specificity of these agonists for
GPR55. LPI is arguably the most well defined GPR55 agonist that does not activate CB1 (AnaviGoffer et al., 2012). LPI is a biologically active lysophospholipid that is produced from
phosphatidylinositide hydrolysis. It has been found in large quantities in the brain (Oka et al.,
2009), and has been linked to inducing ERK ½ phosphorylation to release intracellular calcium
(Oka et al., 2007). In vivo, it has been shown to have neuroprotective properties in a model of
transient global ischemia, specifically in CA1 pyramidal cells, even when given 30 min after the
ischemic insult (Blondeau et al., 2002). This neuroprotective effect could be due to non-receptor
mediated effects such as activating 2-pore domain K+ channels TREK-1 and TRAAK (Maingret
et al., 2000) which would tend to reduce calcium influx through voltage dependent calcium
channels and NMDAR. These channels are important for regulation of membrane potential in
neurons, and could cause hyperpolarization that could influence our results. However
hyperpolarization of neurons would have resulted in a decrease in LTP, rather than the enhanced
LTP that we observed with LPI, making it an unlikely influence on our data. Very recently,
functional LPI was reported in the hippocampus stimulating >6@*73Ȗ6ELQGLQJ in the rat
KLSSRFDPSXVDWȝ0 (Rojo et al., 2012), confirming that it does activate GPCRs in the
hippocampus, but its specific targets are variable. While these studies indicate that it would be a
good choice as a GPR55 agonist in the hippocampus, LPI is also linked to other GPCRs,
including GPR119.
While GPR55 has been activated or silenced by several synthetic cannabinoids and eCBs,
the fact that LPI is the most consistent signaling molecule for GPR55 (Piñeiro and Falasca, 2012)
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raises the question of its endogenous signalling molecules, and whether it binds eCBs, lipid
products, or both. So while both agonists used in this study are reliable for activating GPR55,
neither is perfect in its specificity. More research will need to be done to establish a well-defined
protocol for examining GPR55 in the central nervous system, though by using transgenic mice in
this project we were able to confirm that GPR55 is capable of modulating plasticity in the
hippocampus.

Significance:
The hippocampus is responsible for the tasks of learning and encoding memory. These
processes are not completely understood, since they are extremely complex and multi-faceted.
Synaptic plasticity, or the strengthening or weakening of synaptic connections mediates memory
and learning within the hippocampus. We found that GPR55 is capable of modulating
hippocampal synaptic plasticity, specifically that its activation is capable of increasing CA1 LTP,
a process shown to underlie efficient memory formation. Our findings were vital because of the
great interest we have in preventing both the natural decline of memory that occurs with old age,
and accelerated memory loss observed in neurodegenerative disease. This research may assist us
in better understanding mechanisms of memory formation, thereby opening new channels of
research in therapy development for devastating disorders like Alzheimer’s and dementia. It is
also important to highlight the importance of using GPR55-/- mice to better isolate the effect of
GPR55, and to consider the other effectors of drugs like O-1602 and LPI in order to better
understand synaptic plasticity in the hippocampus.
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FUTURE DIRECTIONS
As stated previously, GPR55-/- mice are necessary to further establish and characterize
GPR55 in the hippocampus. It would be of interest to examine whether LPI induces change in
basal transmission on CA1 interneurons directly using whole cell patch clamp on transgenic
mice. If LPI alters current on GPR55+/+ mice, and not GPR55-/- mice, we will further establish
that LPI is activating GPR55 specifically, and obtain more information about the functional
location of GPR55 in the hippocampus.
If GPR55 does mediate the depression we observed previously in CA1 interneurons, it
could imply that that the increased CA1 LTP we observed is a result of disinhibition, the process
by which CB1 and mGluR receptors can both mediate eCB induced increases in CA1 LTP by
reducing the output of inhibitory interneurons on excitatory CA1 pyramidal cells (Kreitzer and
Regehr, 2002). In order to investigate this possibility, these experiments should be repeated in
the presence of bicuculline, a GABA A antagonist that will isolate the CA3-CA1 excitatory
pyramidal cell synapse. If an increase in LTP is still present with bicuculline in the ACSF, we
will be able to establish that the observed enhancement of LTP is independent of GABA A
interneurons, and therefore whether GPR55 works through disinhibition of CA1 pyramidal cells
similar to CB1.
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FIGURE LEGENDS
Figure 1. GPR55 mRNA expression in rat hippocampus. A) Hippocampal homogenate
demonstrates the presence of GPR55 in 1000 ng (black), 300 ng (red) and 100 ng samples
(cyan). Inset: 4% agarose gel to confirm amplicon size, left to right, 50bp ladder (50 bp, 100 bp,
and 150 bp shown), GPR55 no template control, and GPR55 (76bp).
Figure 2. O-1602 mediates depression of some CA1 interneuron EPSCs, but not CA1 pyramidal
cells. A) Application of O-1602 (5 ȝ0 LQGXFHVVOLJKW p>0.05) depression of EPSCs (EPSC
amplitudes after 10-15 minutes in O-1602; n=8, inset: representative EPSC traces and resistance)
in whole cell recordings of CA1 interneurons but B) significant depression in only a few
interneurons. C) However, no depression was observed in field recordings of CA1 pyramidal
cells (p>0.05, inset: representative EPSP traces).
Figure 3. O-1602 mediates depression of CA1 LTP, but does not alter LTD in the rat. A) O-1602
(1 ȝ0 VLJQLILFDQWO\ p < 0.05; n = 15) decreased theta burst induced LTP as compared to EtOH
vehicle control (0.01%; n = 14) as measured using field excitatory postsynaptic potentials
(fEPSPs). B) O-1602 (1 ȝ0 GLGQRWDOWHU p>0.05; n=8) LTD induced by 1 Hz as compared to
EtOH vehicle control (0.01%; n = 10) as measured using fEPSPs. Error bars indicate SEM.
Inset: representative EPSP traces, scale bar: 100 pA, 10 ms.
Figure 4. GPR55 activation increases CA1 LTP in transgenic mice. A) GPR55-/- mice had
significantly reduced (p<0.05; n=9) theta burst induced LTP as compared to littermate wild-type
controls (n=15) in the presence of lysophosphatidylinositol (LPI; 2 ȝ0  B) LPI (2 ȝ0 KDGD
trend to increase (p>0.05; n=15, from Fig. A) theta burst induced LTP as compared to EtOH
vehicle control (0.05%; n = 13) in GPR55+/+ mice as measured using fEPSPs. C) LPI did not
alter (p > 0.05; n = 9, from Fig. A) theta burst induced LTP in as compared to EtOH vehicle
control (0.05%; n = 8) in GPR55-/- mice as measured using fEPSPs. Error bars indicate SEM.
Inset: representative EPSP traces, scale bar: 100 pA, 10 ms.
Figure 5. O-1602 does not alter long-term potentiation in GPR55-/- mice. The putative GPR55
agonist O-1602 (3 ȝ0 GLGQRWDOWHU p > 0.05; n = 6) theta burst induced LTP in as compared to
EtOH vehicle control (0.05%; n = 5) in GPR55-/- mice as measured using fEPSPs. Error bars
indicate SEM. Inset: representative EPSP traces, scale bar: 100 pA, 10 ms.
Figure 6. GPR55 -/- mice do not have impaired spatial memory compared to littermate GPR55 +/+
controls. A) GPR55 -/-(n=7) and GPR55 +/+ mice (n=7) did not (p>0.05) have different predicted
median escape latency times (sec) in the acquisition period (sessions 1-7) of the Morris water
maze task. Inset represents platform (red) location in pool (blue). B) Close up of sessions 2-7
during acquisition period. C) GPR55 -/-(n=7) and GPR55 +/+ mice (n=7) did not (p>0.05) have
different predicted median escape latency times (sec) in the reversal period (session 8) of the
Morris water maze task. Inset represents platform (red) location in pool (blue) with North (N),
South (S), East (E), and West (W) start locations indicated.
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Figure 4.
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Figure 5.
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APPENDIX
A.

Wild type
Mutant

2.0

Normalized EPSPs

In addition to my thesis project, I
collaborated with Dr. Laura
Bridgewater by collecting
electrophysiological data from
hippocampal slices of nuclear bone
morphogenetic protein 2 (nBmp2)
transgenic mice.
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Normalized EPSPs

Wild type
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2.0

Field recordings from hippocampal
CA1 pyramidal cells of nBmp2
transgenic mice. Theta burst
induced LTP was examined in
nBmp2-/- mice vs. nBmp2+/+ mice to
examine the potential for nBmp2 as
a modulator of synaptic plasticity.
A) We found that nBmp2-/- mice
(n=12) aged 2.5-3.5 months had
significant (p<0.05) reduction
differences in LTP compared to
nBmp2+/+ mice (n=15). B)
However, 3-4 week old nBmp2-/mice (n=8) exhibited no difference
(p>0.05) compared to nBmp2+/+
mice (n=5), indicating a potential
developmental change in expression
or function for hippocampal nBMP2
in mice.
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